Literature DB >> 22957518

Actinide chelation: biodistribution and in vivo complex stability of the targeted metal ions.

Birgitta Kullgren1, Erin E Jarvis, Dahlia D An, Rebecca J Abergel.   

Abstract

Because of the continuing use of nuclear fuel sources and heightened threats of nuclear weapon use, the amount of produced and released radionuclides is increasing daily, as is the risk of larger human exposure to fission product actinides. A rodent model was used to follow the in vivo distribution of representative actinides, administered as free metal ions or complexed with chelating agents including diethylenetriamine pentaacetic acid (DTPA) and the hydroxypyridinonate ligands 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO). Different metabolic pathways for the different metal ions were evidenced, resulting in intricate ligand- and metal-dependent decorporation mechanisms. While the three studied chelators are known for their unrivaled actinide decorporation efficiency, the corresponding metal complexes may undergo in vivo decomposition and release metal ions in various biological pools. This study sets the basis to further explore the metabolism and in vivo coordination properties of internalized actinides for the future development of viable therapeutic chelating agents.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22957518     DOI: 10.3109/15376516.2012.728641

Source DB:  PubMed          Journal:  Toxicol Mech Methods        ISSN: 1537-6516            Impact factor:   2.987


  8 in total

Review 1.  World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Authors:  Christina N Kontoghiorghe; Nicholas Andreou; Katerina Constantinou; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2014-09-26

2.  Design and synthesis of N-hydroxyalkyl substituted deferiprone: a kind of iron chelating agents for Parkinson's disease chelation therapy strategy.

Authors:  Qingchun Zhang; Shufan Feng; Yulian Zhao; Bo Jin; Rufang Peng
Journal:  J Biol Inorg Chem       Date:  2021-05-08       Impact factor: 3.358

3.  Identification of process related trace level impurities in the actinide decorporation agent 3,4,3-LI(1,2-HOPO): Nozzle-skimmer fragmentation via ESI LC-QTOFMS.

Authors:  Nagender R Panyala; Manuel Sturzbecher-Hoehne; Rebecca J Abergel
Journal:  J Pharm Biomed Anal       Date:  2014-08-12       Impact factor: 3.935

4.  From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents.

Authors:  Dahlia D An; Birgitta Kullgren; Erin E Jarvis; Rebecca J Abergel
Journal:  Chem Biol Interact       Date:  2016-03-31       Impact factor: 5.192

5.  New insights into structure and luminescence of Eu(III) and Sm(III) complexes of the 3,4,3-LI(1,2-HOPO) ligand.

Authors:  Lena J Daumann; David S Tatum; Benjamin E R Snyder; Chengbao Ni; Ga-lai Law; Edward I Solomon; Kenneth N Raymond
Journal:  J Am Chem Soc       Date:  2015-02-19       Impact factor: 15.419

6.  A 3,2-Hydroxypyridinone-based Decorporation Agent that Removes Uranium from Bones In Vivo.

Authors:  Xiaomei Wang; Xing Dai; Cen Shi; Jianmei Wan; Mark A Silver; Linjuan Zhang; Lanhua Chen; Xuan Yi; Bizheng Chen; Duo Zhang; Kai Yang; Juan Diwu; Jianqiang Wang; Yujie Xu; Ruhong Zhou; Zhifang Chai; Shuao Wang
Journal:  Nat Commun       Date:  2019-06-25       Impact factor: 14.919

7.  In situ beam reduction of Pu(IV) and Bk(IV) as a route to trivalent transuranic coordination complexes with hydroxypyridinone chelators.

Authors:  Korey P Carter; Jennifer N Wacker; Kurt F Smith; Gauthier J P Deblonde; Liane M Moreau; Julian A Rees; Corwin H Booth; Rebecca J Abergel
Journal:  J Synchrotron Radiat       Date:  2022-02-25       Impact factor: 2.616

Review 8.  The toxicological mechanisms and detoxification of depleted uranium exposure.

Authors:  Yong-Chao Yue; Ming-Hua Li; Hai-Bo Wang; Bang-Le Zhang; Wei He
Journal:  Environ Health Prev Med       Date:  2018-05-16       Impact factor: 3.674

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.